Withdrawal of mycophenolate mofetil in stable renal transplant recipients

Bruce Kaplan, Herwig Ulf Meier-Kriesche, Mahesh Vaghela, Gary Friedman, Shamkant Mulgaonkar, Martin Jacobs

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background. Mycophenolate mofetil (MMF) has been demonstrated to decrease episodes of acute rejection in renal transplant recipients during the first year after transplantation. The utility of MMF after 1 year is less clear. Methods. Forty-five stable renal transplant recipients on maintenance therapy of cyclosporine microemulsion, MMF, and prednisone had MMF withdrawn at approximately 1 year after transplantation. A matching concurrent group of 45 stable renal transplant recipients served as the case control group. Results. Two of 45 patients in the MMF withdrawal group suffered an acute rejection episode as opposed to 1 of 45 in the control group. Both patients who rejected in the withdrawal group had adequate cyclosporine levels and had no recent decrease in prednisone dose. There was no evidence of an increased incidence of proteinuria or increased creatinine levels in the MMF withdrawal group. Conclusion. In general, withdrawal of MMF in stable renal transplant recipients is well tolerated. No increased risk of rejection could be demonstrated in this patient group. A larger study will be needed to confirm our result.

Original languageEnglish (US)
Pages (from-to)1726-1728
Number of pages3
JournalTransplantation
Volume69
Issue number8
StatePublished - Apr 27 2000
Externally publishedYes

Fingerprint

Mycophenolic Acid
Kidney
Prednisone
Cyclosporine
Transplantation
Control Groups
Transplant Recipients
Proteinuria
Creatinine
Incidence

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Kaplan, B., Meier-Kriesche, H. U., Vaghela, M., Friedman, G., Mulgaonkar, S., & Jacobs, M. (2000). Withdrawal of mycophenolate mofetil in stable renal transplant recipients. Transplantation, 69(8), 1726-1728.

Withdrawal of mycophenolate mofetil in stable renal transplant recipients. / Kaplan, Bruce; Meier-Kriesche, Herwig Ulf; Vaghela, Mahesh; Friedman, Gary; Mulgaonkar, Shamkant; Jacobs, Martin.

In: Transplantation, Vol. 69, No. 8, 27.04.2000, p. 1726-1728.

Research output: Contribution to journalArticle

Kaplan, B, Meier-Kriesche, HU, Vaghela, M, Friedman, G, Mulgaonkar, S & Jacobs, M 2000, 'Withdrawal of mycophenolate mofetil in stable renal transplant recipients', Transplantation, vol. 69, no. 8, pp. 1726-1728.
Kaplan B, Meier-Kriesche HU, Vaghela M, Friedman G, Mulgaonkar S, Jacobs M. Withdrawal of mycophenolate mofetil in stable renal transplant recipients. Transplantation. 2000 Apr 27;69(8):1726-1728.
Kaplan, Bruce ; Meier-Kriesche, Herwig Ulf ; Vaghela, Mahesh ; Friedman, Gary ; Mulgaonkar, Shamkant ; Jacobs, Martin. / Withdrawal of mycophenolate mofetil in stable renal transplant recipients. In: Transplantation. 2000 ; Vol. 69, No. 8. pp. 1726-1728.
@article{d5b58a98c6b1494f9e50c9c8a1b7b1dc,
title = "Withdrawal of mycophenolate mofetil in stable renal transplant recipients",
abstract = "Background. Mycophenolate mofetil (MMF) has been demonstrated to decrease episodes of acute rejection in renal transplant recipients during the first year after transplantation. The utility of MMF after 1 year is less clear. Methods. Forty-five stable renal transplant recipients on maintenance therapy of cyclosporine microemulsion, MMF, and prednisone had MMF withdrawn at approximately 1 year after transplantation. A matching concurrent group of 45 stable renal transplant recipients served as the case control group. Results. Two of 45 patients in the MMF withdrawal group suffered an acute rejection episode as opposed to 1 of 45 in the control group. Both patients who rejected in the withdrawal group had adequate cyclosporine levels and had no recent decrease in prednisone dose. There was no evidence of an increased incidence of proteinuria or increased creatinine levels in the MMF withdrawal group. Conclusion. In general, withdrawal of MMF in stable renal transplant recipients is well tolerated. No increased risk of rejection could be demonstrated in this patient group. A larger study will be needed to confirm our result.",
author = "Bruce Kaplan and Meier-Kriesche, {Herwig Ulf} and Mahesh Vaghela and Gary Friedman and Shamkant Mulgaonkar and Martin Jacobs",
year = "2000",
month = "4",
day = "27",
language = "English (US)",
volume = "69",
pages = "1726--1728",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Withdrawal of mycophenolate mofetil in stable renal transplant recipients

AU - Kaplan, Bruce

AU - Meier-Kriesche, Herwig Ulf

AU - Vaghela, Mahesh

AU - Friedman, Gary

AU - Mulgaonkar, Shamkant

AU - Jacobs, Martin

PY - 2000/4/27

Y1 - 2000/4/27

N2 - Background. Mycophenolate mofetil (MMF) has been demonstrated to decrease episodes of acute rejection in renal transplant recipients during the first year after transplantation. The utility of MMF after 1 year is less clear. Methods. Forty-five stable renal transplant recipients on maintenance therapy of cyclosporine microemulsion, MMF, and prednisone had MMF withdrawn at approximately 1 year after transplantation. A matching concurrent group of 45 stable renal transplant recipients served as the case control group. Results. Two of 45 patients in the MMF withdrawal group suffered an acute rejection episode as opposed to 1 of 45 in the control group. Both patients who rejected in the withdrawal group had adequate cyclosporine levels and had no recent decrease in prednisone dose. There was no evidence of an increased incidence of proteinuria or increased creatinine levels in the MMF withdrawal group. Conclusion. In general, withdrawal of MMF in stable renal transplant recipients is well tolerated. No increased risk of rejection could be demonstrated in this patient group. A larger study will be needed to confirm our result.

AB - Background. Mycophenolate mofetil (MMF) has been demonstrated to decrease episodes of acute rejection in renal transplant recipients during the first year after transplantation. The utility of MMF after 1 year is less clear. Methods. Forty-five stable renal transplant recipients on maintenance therapy of cyclosporine microemulsion, MMF, and prednisone had MMF withdrawn at approximately 1 year after transplantation. A matching concurrent group of 45 stable renal transplant recipients served as the case control group. Results. Two of 45 patients in the MMF withdrawal group suffered an acute rejection episode as opposed to 1 of 45 in the control group. Both patients who rejected in the withdrawal group had adequate cyclosporine levels and had no recent decrease in prednisone dose. There was no evidence of an increased incidence of proteinuria or increased creatinine levels in the MMF withdrawal group. Conclusion. In general, withdrawal of MMF in stable renal transplant recipients is well tolerated. No increased risk of rejection could be demonstrated in this patient group. A larger study will be needed to confirm our result.

UR - http://www.scopus.com/inward/record.url?scp=0034720058&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034720058&partnerID=8YFLogxK

M3 - Article

C2 - 10836389

AN - SCOPUS:0034720058

VL - 69

SP - 1726

EP - 1728

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 8

ER -